DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy
暂无分享,去创建一个
Ke Zhou | Haiyang Xie | Shusen Zheng | Wei Zhang | Jiahua Lu | Changku Jia | Liang Zhang | Zhentao Yang | Donghai Jiang | Jiawei Hong | Hong Tang | Wei Chen | Xi Liu
[1] Haiyang Xie,et al. Asialoglycoprotein receptor 1 functions as a tumor suppressor in liver cancer via inhibition of STAT3. , 2022, Cancer research.
[2] S. Jon,et al. Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma , 2022, Molecular therapy oncolytics.
[3] Ke Zhou,et al. Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation , 2022, Journal of inflammation research.
[4] Shi Feng,et al. MiR-516a-3p is a Novel Mediator of Hepatocellular Carcinoma Oncogenic Activity and Cellular Metabolism , 2021, Engineering.
[5] D. Levy,et al. IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca2+ through the noncanonical STAT3 pathway , 2021, Proceedings of the National Academy of Sciences.
[6] Shusen Zheng,et al. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response , 2021, Journal for ImmunoTherapy of Cancer.
[7] Yi Hou,et al. miR-30d-5p represses the proliferation, migration, and invasion of lung squamous cell carcinoma via targeting DBF4 , 2021, Journal of environmental science and health. Part C, Toxicology and carcinogenesis.
[8] R. Bernards,et al. Exploring liver cancer biology through functional genetic screens , 2021, Nature Reviews Gastroenterology & Hepatology.
[9] Zehua Wang,et al. Lactate induces aberration in the miR-30a–DBF4 axis to promote the development of gastric cancer and weakens the sensitivity to 5-Fu , 2021, Cancer Cell International.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] A. Azmi,et al. The nuclear export protein XPO1 — from biology to targeted therapy , 2020, Nature Reviews Clinical Oncology.
[12] Wei Huang,et al. Targeting STAT3 in Cancer Immunotherapy , 2020, Molecular cancer.
[13] Shi Feng,et al. The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill , 2020, Frontiers in Oncology.
[14] V. E. Pye,et al. Structural Basis for the Activation and Target Site Specificity of CDC7 Kinase , 2020, Structure.
[15] K. Wennerberg,et al. Identification of novel regulators of STAT3 activity , 2020, PloS one.
[16] Ke Zhou,et al. Protein Profiles of Pretransplant Grafts Predict Early Allograft Dysfunction After Liver Transplantation From Donation After Circulatory Death , 2020, Transplantation.
[17] Yifeng Zhou,et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis , 2019, The Journal of experimental medicine.
[18] H. Cohen,et al. Cancer statistics for adults aged 85 years and older, 2019 , 2019, CA: a cancer journal for clinicians.
[19] R. Bernards,et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer , 2019, Nature.
[20] M. Malafa,et al. Importins and exportins as therapeutic targets in cancer. , 2016, Pharmacology & therapeutics.
[21] Lanjuan Li,et al. Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells , 2015, Nature Communications.
[22] J. Diffley,et al. Regulated Eukaryotic DNA Replication Origin Firing with Purified Proteins , 2015, Nature.
[23] Megan C King,et al. Macromolecular transport between the nucleus and the cytoplasm: Advances in mechanism and emerging links to disease. , 2014, Biochimica et biophysica acta.
[24] S. Gery,et al. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma , 2014, Cancer Chemotherapy and Pharmacology.
[25] A. Guarné,et al. Dbf4: The whole is greater than the sum of its parts , 2013, Cell cycle.
[26] Lan-juan Li,et al. Advances in cell sources of hepatocytes for bioartificial liver. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.
[27] Lanjuan Li,et al. Establishment and characterization of immortalized human hepatocyte cell line for applications in bioartificial livers , 2012, Biotechnology Letters.
[28] Wei Xu,et al. Discovery of XL413, a potent and selective CDC7 inhibitor. , 2012, Bioorganic & medicinal chemistry letters.
[29] A. Montagnoli,et al. Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy , 2010, Clinical Cancer Research.
[30] Bruce Stillman,et al. The Dbf4-Cdc7 kinase promotes S phase by alleviating an inhibitory activity in Mcm4 , 2009, Nature.
[31] Charlotta Lindvall,et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. , 2008, Neoplasia.
[32] J. Hegemann,et al. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. , 2007, Carcinogenesis.
[33] Hoyun Lee,et al. Identification and Characterization of Human Cdc7 Nuclear Retention and Export Sequences in the Context of Chromatin Binding* , 2007, Journal of Biological Chemistry.
[34] Xinmin Cao,et al. The Coiled-Coil Domain of Stat3 Is Essential for Its SH2 Domain-Mediated Receptor Binding and Subsequent Activation Induced by Epidermal Growth Factor and Interleukin-6 , 2000, Molecular and Cellular Biology.
[35] F. Giles,et al. Cdc7 kinase - a new target for drug development. , 2010, European journal of cancer.